FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH DRAFT AGENDA (revised 2/9/04)

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE February 18 & 19, 2004

Sheraton Four-Points Hotel, 8400 Wisconsin Ave., Bethesda, Maryland

Wednesday, February 18, 2004

8:30 a	a.m. (Call to Order	Dr. Gary Overturf, Chair
	8:35	Administrative Matters	Dr. Bill Freas
	8:40	Presentation of Plaques to Retiring Members	Dr. Karen Midthun
8:50 <u>OPEN Session</u> Strain Selection for Influenza Virus Vaccine for the 2004-2005 Season			
	8:50	Introduction	Dr. Roland Levandowski, FDA
	9:50	Vaccine Effectiveness	Dr. Carolyn Bridges, CDC Col. James Neville, DOD Dr. Antoine Flahault, INSERM, Paris
	11:20	Break	
	11:30	U.S. Surveillance	Ann Moen, CDC
12:00 p.m.		Lunch	
1:00	Open Public Hearing		
	1:30	World Surveillance and Strain Characterization Strain Characterization	Dr. Nancy Cox, CDC
	2:00	Additional Reports	Linda Canas, DOD Dr. Maria Zambon, HPA, UK
3:00	Break		
	3:30	Vaccine Responses	Dr. Roland Levandowski, FDA
	4:00	Availability of Strains and Reagents	Dr. Zhiping Ye, FDA
	4:15	Comments from Manufacturers	
5:00 Update on H5 7:00 p.m. Adjourn			Dr. Nancy Cox, CDC Dr. Phil Minor, NIBSC NIH Speaker (TBA)

AGENDA (Continued) VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

<u>Second Day</u> Thursday, February 19, 2004

8:30 a.m. Call to Order

8:35 Announcements

OPEN Session

Strain Selection for Influenza Virus Vaccine for the 2004-2005 Season

8:45Open Public Hearing9:15Options for Strain SelectionDr. Roland Levandowski, FDA9:35Committee Discussion and Recommendations10:45Break11:00Mammalian Tissue Culture Used in Vaccine Prepartion
FDA Perspective
NIBSC PerspectiveDr. Zhiping Ye, FDA
Dr. Phil Minor, NIBSC

1:00 p.m. Adjourn